Brown Lisle Cummings Inc. Has $4.20 Million Stake in Novo Nordisk A/S (NYSE:NVO)

Brown Lisle Cummings Inc. cut its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 2.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 48,858 shares of the company’s stock after selling 1,337 shares during the quarter. Novo Nordisk A/S comprises 1.3% of Brown Lisle Cummings Inc.’s portfolio, making the stock its 18th biggest holding. Brown Lisle Cummings Inc.’s holdings in Novo Nordisk A/S were worth $4,203,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. AQR Capital Management LLC boosted its holdings in shares of Novo Nordisk A/S by 110.5% during the 2nd quarter. AQR Capital Management LLC now owns 17,164 shares of the company’s stock worth $2,450,000 after buying an additional 9,012 shares during the period. WealthBridge Capital Management LLC grew its position in shares of Novo Nordisk A/S by 8.4% in the third quarter. WealthBridge Capital Management LLC now owns 6,780 shares of the company’s stock valued at $807,000 after purchasing an additional 525 shares during the last quarter. Azzad Asset Management Inc. ADV increased its stake in shares of Novo Nordisk A/S by 55.9% during the third quarter. Azzad Asset Management Inc. ADV now owns 41,107 shares of the company’s stock worth $4,895,000 after purchasing an additional 14,731 shares during the period. Parisi Gray Wealth Management lifted its holdings in Novo Nordisk A/S by 19.6% during the 3rd quarter. Parisi Gray Wealth Management now owns 3,990 shares of the company’s stock worth $475,000 after purchasing an additional 653 shares during the last quarter. Finally, Salvus Wealth Management LLC grew its holdings in Novo Nordisk A/S by 6.9% in the 3rd quarter. Salvus Wealth Management LLC now owns 3,064 shares of the company’s stock valued at $365,000 after buying an additional 198 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 2.1 %

Shares of Novo Nordisk A/S stock opened at $82.64 on Tuesday. The firm has a market capitalization of $370.85 billion, a PE ratio of 26.74, a price-to-earnings-growth ratio of 0.93 and a beta of 0.45. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The firm’s 50 day moving average is $93.56 and its 200 day moving average is $112.87. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.